Département de pharmacologie et physiologie, Université de Montréal, Montreal, QC, H3T 1J4, Canada.
Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montreal, QC, H3T 1J4, Canada.
Sci Rep. 2018 Mar 5;8(1):3990. doi: 10.1038/s41598-018-22400-y.
The cytokines CLCF1 and CNTF are ligands for the CNTF receptor and the apolipoprotein E (ApoE) receptor sortilin. Both share structural similarities with the N-terminal domain of ApoE, known to bind CNTF. We therefore evaluated whether ApoE or ApoE-containing lipoproteins interact with CLCF1 and regulate its activity. We observed that CLCF1 forms complexes with the three major isoforms of ApoE in co-immunoprecipitation and proximity assays. FPLC analysis of mouse and human sera mixed with CLCF1 revealed that CLCF1 co-purifies with plasma lipoproteins. Studies with sera from ApoE mice indicate that ApoE is not required for CLCF1-lipoprotein interactions. VLDL- and LDL-CLCF1 binding was confirmed using proximity and ligand blots assays. CLCF1-induced STAT3 phosphorylation was significantly reduced when the cytokine was complexed with VLDL. Physiological relevance of our findings was asserted in a mouse model of oxygen-induced retinopathy, where the beneficial anti-angiogenic properties of CLCF1 were abrogated when co-administrated with VLDL, indicating, that CLCF1 binds purified lipoproteins or lipoproteins in physiological fluids such as serum and behave as a "lipocytokine". Albeit it is clear that lipoproteins modulate CLCF1 activity, it remains to be determined whether lipoprotein binding directly contributes to its neurotrophic function and its roles in metabolic regulation.
细胞因子 CLCF1 和 CNTF 是 CNTF 受体和载脂蛋白 E(ApoE)受体分选素的配体。两者都与已知与 CNTF 结合的 ApoE N 端结构域具有结构相似性。因此,我们评估了 ApoE 或含 ApoE 的脂蛋白是否与 CLCF1 相互作用并调节其活性。我们观察到 CLCF1 在共免疫沉淀和接近测定中与 ApoE 的三种主要同工型形成复合物。用 CLCF1 混合的小鼠和人血清进行 FPLC 分析表明,CLCF1 与血浆脂蛋白共纯化。来自 ApoE 小鼠的血清研究表明,ApoE 不是 CLCF1-脂蛋白相互作用所必需的。使用接近和配体印迹测定证实了 VLDL 和 LDL-CLCF1 的结合。当细胞因子与 VLDL 复合时,CLCF1 诱导的 STAT3 磷酸化显著降低。我们在氧诱导的视网膜病变小鼠模型中的发现具有生理相关性,其中当与 VLDL 共同给药时,CLCF1 的有益抗血管生成特性被废除,表明 CLCF1 结合纯化的脂蛋白或生理液(如血清)中的脂蛋白,并且作为“脂细胞因子”发挥作用。虽然很明显脂蛋白可以调节 CLCF1 的活性,但脂蛋白结合是否直接有助于其神经营养功能及其在代谢调节中的作用仍有待确定。